Related Experiment Video
Updated: Apr 5, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
1.0K
CD146 as an adverse prognostic factor in uterine sarcoma
Yun Zhou1,2,3, He Huang4,5,6, Lin-Jing Yuan7,8,9
1Department of Gynecology Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. zhouyun@sysucc.org.cn.
European Journal of Medical Research
|August 22, 2015
Summary
Uterine sarcoma biomarkers CD146, P53, and Ki-67 are overexpressed. CD146 expression correlates with metastasis and poor survival in leiomyosarcoma, suggesting its potential as a prognostic marker.
Area of Science:
- Oncology
- Pathology
Background:
- Uterine sarcoma is an aggressive cancer with a poor prognosis.
- Identifying reliable prognostic markers is crucial for improving patient outcomes.
Purpose of the Study:
- To determine the expression levels of CD146, P53, and Ki-67 in uterine sarcoma.
- To evaluate the prognostic significance of these markers in uterine sarcoma patients.
Main Methods:
- Retrospective analysis of 68 uterine sarcoma patients.
- Immunohistochemical analysis of CD146, P53, and Ki-67 expression in tumor tissues.
- Correlation of marker expression with clinicopathologic features and survival data.
Main Results:
- The 5-year overall survival rate was 46%.
- CD146 was overexpressed in 32% of endometrial stromal sarcoma (ESS) and 69.4% of leiomyosarcoma (LMS) cases.
- CD146 overexpression correlated with lymph node metastasis (P=0.021) and Ki-67 overexpression (P=0.0053) in LMS.
Conclusions:
- CD146, P53, and Ki-67 are frequently overexpressed in uterine sarcoma.
- CD146 expression is linked to lymph node metastasis and poorer overall survival in LMS.
- CD146 may serve as a valuable prognostic marker for leiomyosarcoma.
